Items where authors include "Palmer, DH"

Article

Loughney, L, West, MA, Moyses, H et al. (13 more authors) (2021) The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial). Perioperative Medicine, 17 (1). 23. ISSN 2047-0525

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22 (7). e288-e289. ISSN 1470-2045

Lamarca, A, Palmer, DH, Wasan, HS et al. (18 more authors) (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 22 (5). pp. 690-701. ISSN 1470-2045

Jones, CM, Radhakrishna, G, Aitken, K et al. (15 more authors) (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 123 (5). pp. 709-713. ISSN 0007-0920

Jones, RP, Psarelli, E-E, Jackson, R et al. (38 more authors) (2019) Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surgery, 154 (11). pp. 1038-1048. ISSN 2168-6254

Primrose, JN, Fox, RP, Palmer, DH et al. (26 more authors) (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5). pp. 663-673. ISSN 1213-9432

Backen, AC, Lopes, A, Wasan, H et al. (16 more authors) (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 119 (1). pp. 27-35. ISSN 0007-0920

Elander, NO, Aughton, K, Ghaneh, P et al. (25 more authors) (2018) Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118 (8). pp. 1084-1088. ISSN 0007-0920

Elander, NO, Aughton, K, Ghaneh, P et al. (25 more authors) (2018) Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 118 (7). pp. 947-954. ISSN 0007-0920

Meyer, T, Fox, R, Ma, YT et al. (15 more authors) (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology, 2 (8). pp. 565-575. ISSN 2468-1253

Neoptolemos, JP, Palmer, DH, Ghaneh, P et al. (31 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, 389 (10073). pp. 1011-1024. ISSN 0140-6736

Loughney, L, West, MA, Kemp, GJ et al. (9 more authors) (2016) The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): Study protocol for a randomised controlled trial. Trials, 17. 24. ISSN 1745-6215